Healthcare Business News

ASHEVILLE, NC–(Marketwire – September 29, 2010) –  Jaan Ferree, an interior designer based in Asheville, NC specializes in designing public spaces for healthcare, colleges, churches and retreats. Asheville City Council appointed Ferree to the Public Art Board. Her interior design ideas include work by Western North Carolina (WNC) artists and craftsmen.

North Carolina Arts for Health invited Ferree to speak at the Spirit of Place, Places of Spirit conference on October 16, 2010, co-sponsored by Mountain Area Health Education Center (MAHEC). She will present an overview of her intentional process of creating healing environments for health care professionals, patients and families. In these sacred spaces, the public can meditate, nurture their spirits, and connect with the divine in a soothing environment. Participants will tour Mission Hospital chapels. 

Ferree recently completed the interior design of Saint Joseph’s Chapel, a three-year process bringing an interfaith focus to Mission Hospital chapels. To the right of the entrance, the Chapel of Mercy resembles a mini church design, with chairs, kneelers, pew and Stations of the Cross. A glass case across from this room holds symbols of various religions: Buddha, Shiva/Shakti, sage bundles and a feather, a Quran, prayer rug, and Islamic prayer beads and a Menorah. The chapel incorporates signatures of Ferree’s work — a labyrinth walk, journaling table, original stained glass pieces hanging from the skylight, an enlarged photograph of an apple tree in bloom, and a murmuring fountain to complete the overall feeling of calm and serenity. 

“What drew us to Jaan was her inclusion of local artistry and nature in her design aesthetic, her experience in designing labyrinths, and her dedication to creating a space which invites all to enter and encounter the holy,” commented Jerene Broadway, Staff Chaplain for Mission Hospital. “We were delighted to discover that her design and leadership embodied our vision to weave diverse religious traditions into a single tapestry,” she added.

Ferree has designed indoor and outdoor labyrinths, meditation gardens and sacred interior spaces for churches and retreat centers, including Valle Crucis Conference Center, Davidson College and Carpe Diem Farms. She will design an outdoor pavilion for use as a meditation and yoga center at Horse Sense of the Carolinas, where equine therapy is practiced.

To view samples of Jaan Ferree’s interior designs, or for a consultation, visit Intentional Designer, email [email protected] or call 828-252-8718. 

SAN CLEMENTE, CA–(Marketwire – September 29, 2010) –  Micro Identification Technologies, Inc. (OTCBB: MMTC) (MIT) announces that it has entered into a Securities Purchase Agreement in the form of an 8% convertible note with a New York-based privately held investment banking firm. The Note matures on May 18, 2011 and is convertible into common shares. The firm may convert any or the entire unpaid principal note prior to the maturity date, commencing 180 days following the date of the Note.

This funding is in addition to our recent announcement of the equity financing commitment from Dutchess Capital. MIT expects to receive additional funding from this or other firms under similar conditions in the upcoming months to accelerate its planned production launch and marketing campaign later this year. MIT’s Chairman and CEO, Michael Brennan, stated, “This funding will significantly help MIT achieve its near term goals and, together with expected future funding, will enable MIT to exceed its short and medium term plans.”

MIT will be hosting a Webinar at 1:00 PM PDT today to provide an update of its current business and future plans. Attendees may register for this Event at: https://www3.gotomeeting.com/register/427693966

About Micro Identification Technologies:

MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-identification.com

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT has performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

SAN CLEMENTE, CA–(Marketwire – September 27, 2010) – Micro Identification Technologies, Inc. (OTCBB: MMTC), a California-based public company and creator of an advanced rapid microbial identification system, announced today that it will host a 30 minute Webinar on Wednesday, September 29, 2010 at 1:00 pm (PDT). The objective of the Webinar is to provide a general Business Update to current and prospective customers and investors. John Ricardi, MIT’s Executive Vice President, will give the presentation that will be followed by an open question and answer session with MIT’s staff including its Chairman and CEO, Michael Brennan.

Attendees may register for this Event at https://www3.gotomeeting.com/register/427693966. The session will be recorded and placed on MIT’s website for those people who are unable to attend. If you are having trouble registering or would like more information, please contact the Company at [email protected].

About Micro Identification Technologies:

MIT has developed, patented and produces a rapid microbial identification (ID) System that revolutionizes the bacteria ID process and can annually save thousands of lives and tens of millions of healthcare dollars. The MIT 1000 System identifies bacteria in minutes, not days, and at significant cost per test savings when compared to any conventional method — it is not reliant on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis — requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 10.2 percent annually reaching $6.2 billion by 2013 and driven by major health, safety and homeland security issues.

The MIT 1000 System can identify bacteria in less than five minutes after culturing at a cost of less than 10 cents per test and is a certified AOAC Research Institute (RI) test method of Listeria, one of three bacteria (the others are Salmonella and E.coli) that are responsible for most of the worldwide food contamination events. The Company is in the process of preparing the MIT 1000 System to become AOAC RI certified later this year for the presence of all “three” bacteria with a single mouse click. The AOAC RI Report and Certification are available from the Company. www.aoac.org 

Further, MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, MRSA and other pathogenic bacteria. MIT recently performed over 300 tests for the identification of these contaminants and scored 95 percent in accuracy. The System’s database currently enables the identification of over twenty species of bacteria and is easily expandable. This identification process has also been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized bioscience testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, documents the accuracy, speed and cost effectiveness of the MIT System over conventional processes. www.namsa.com

Please visit our website: www.micro-identification.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, referencing: “MMTC”

PARIS–(Marketwire – September 23, 2010) – First half-year Financial Information as of June30, 2010

IFRS – Regulated information – Audited

Cegedim: Half-year net profit up 15.6% to ?19.9 million

First half 2010 marked by a strong dynamic commercial performance

Paris, September 23, 2010 – Cegedim, a global technology and services company specializing in the healthcare field, announces consolidated net profit of ?19.9 million for the first half of 2010, up 15.6% over the year-earlier period.

The first half was marked by numerous commercial successes, proving that Cegedim’s range of products and services is well suited to market demand, and that its recent acquisitions hold great promise.

– Simplified income statement

+-------------------------+---------+-------+-------+---------+---------+
|                         |  H1 2010|       |       |  H1 2009|         |
+-------------------------+---------+-------+-------+---------+---------+
|?M                       |        %|       |     ?M|        %|         |
+-------------------------+---------+-------+-------+---------+---------+
|Revenues                 |    448.8|       |  433.9|         |    +3.4%|
+-------------------------+---------+-------+-------+---------+---------+
|EBITDA from ordinary     |     84.1|       |   88.3|         |    -4.7%|
|activities               |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Depreciation             |    -33.5|       |  -34.2|         |    -2.0%|
+-------------------------+---------+-------+-------+---------+---------+
|Operating profit from    |     50.6|  11.3%|   54.1|    12.5%|    -6.4%|
|ordinary activities      |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Other exceptional        |     -5.4|       |   -4.7|         |   +17.0%|
|operating revenues /     |         |       |       |         |         |
|expenses                 |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Operating profit         |     45.2|  10.1%|   49.4|    11.4%|    -8.6%|
+-------------------------+---------+-------+-------+---------+---------+
|Net cost of financial    |    -21.6|       |  -29.8|         |   -27.6%|
|debt                     |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Tax expenses             |     -4.1|       |   -2.7|         |  +49.1% |
+-------------------------+---------+-------+-------+---------+---------+
|Share of earnings of     |      0.4|       |    0.4|         |     n s |
|equity-accounted         |         |       |       |         |         |
|affiliates               |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Consolidated net profit  |     19.9|       |   17.2|         |   +15.6%|
+-------------------------+---------+-------+-------+---------+---------+
|Group share of net profit|     19.8|       |   17.2|         |   +15.2%|
+-------------------------+---------+-------+-------+---------+---------+

Consolidated H1 2010 revenues amounted to ?448.8 million, up 0.4% like for like* and 3.4% on a reported basis. As expected, second-quarter growth of 3.8% like for like* and 8.0% on a reported basis offset the first-quarter decline.

The fact that every Group sector made a positive contribution to revenue growth in the second quarter, both like for like* and on a reported basis, is proof of Cegedim’s dynamic sales performance.

Operating profit from ordinary activities came to ?50.6 million, down 6.4% compared with the first half of 2009. This dip is attributable to an increase in personnel costs, which rose 6.2% due to delays implementing certain large-scale CRM projects.

Thus, margin decreased from 12.5% to 11.3%, despite a fine improvement in Healthcare Professionals and Insurance and services sector margins.

Consolidated net profit rose 15.6% compared with a year earlier to ?19.9 million. The biggest contribution to the increase came from lower interest charges on debt, which fell from ?21.4 million to ?10.6 million due to a drop in the average level of outstanding financial debt.

Consolidated net profit attributable to the Group amounted to ?19.8 million, a 15.2% increase over the first half of 2009. Earnings per share amounted to ?1.4, against ?1.8 last year. The increase of the number of shares following the ?180.5 million capital issue of December 2009 explains the drop in EPS.

Sector business trends

– CRM and strategic data

In the first half of 2010, sector revenues rose 3.5% on a reported basis to ?249.1 million. Currency effects and acquisitions helped boost revenues by 1.9% and 2.9% respectively over the first half. Like-for-like revenues fell slightly, by 1.4%. As expected, the 4.8% rise in Q2 revenues helped offset the drop in Q1 caused by delays in executing certain large-scale projects.

One impact of these delays was an increase in personnel costs, which hurt the sector’s operating margin. The sector’s operating profit from ordinary activities was ?18.3 million, down ?6.0 million compared with H1 2009. As a result, operating margin from ordinary activities was 7.3%, versus 10.1% a year earlier.

Second-quarter revenues testify to the sector’s substantial sales momentum, successful geographic expansion of new services, and the beneficial impact of launching new Mobile Intelligence offerings – particularly the SaaS version – with both current and new clients.

Able to integrate SK&A both operationally and commercially in just six months, Cegedim is now fully profiting from the successful strengthening of its OneKey offering in the USA.

These performances lend credence to the Group’s strategic choices: a global presence as a result of the Dendrite acquisition, particularly in rapidly growing markets such as emerging countries; expanding platforms (iPad® and iPhone®, BlackBerry®, etc.); a richer compliance offering in Europe; bringing Dendrite’s business model in line with that of Cegedim (services vs. licenses); and continuing to make substantial investments in R&D to support new products.

The strategic data activity posted a clear rebound in its revenues and profitability in the second quarter. The Group expects this trend to continue in the months ahead.

– Healthcare professionals

Sector first-half 2010 revenues were ?138.7 million, up 0.8% on a reported basis and stable on a like-for-like* basis. Growth of 1.3% in the second quarter offset the slight first-quarter decline, as expected.

Currency effects and acquisitions boosted first-half revenues by 0.5% and 0.4% respectively.

Operating profit from ordinary activities rose 4.2% to ?23.8 million, reflecting a sizeable 60bp increase in the margin to 17.2%. This result is especially remarkable considering that the sector margin was hurt by the wait-and-see attitude of UK physicians and the expected drop in Cegelease’s margin.

The Group continues to generate impressive performances in France, Spain and Italy. In the UK, Cegedim is convinced that it is in a position to profit from new opportunities arising from a reorganization of the UK healthcare system over the coming years.

Lastly, we note that the RMI (paramedic software) and RNP activities (promotional information for pharmacists) continue to turn in very fine performances in terms of revenues and profitability.

After the close of the first-half financial statements, Cegedim’s acquired Pulse, a US company specializing in electronic healthcare records (EHR) management. In the second half, this move will propel the Cegedim Healthcare Software division onto the global stage, positioning the division to capitalize on the considerable new opportunities in this market. For more information on the deal, please see the “Important post-closing transactions and events” section on page 5.

– Insurance and services

Sector revenues rose 9.9% on both a like-for-like* and a reported basis to ?61 million. Insurance and services activities continued to grow by nearly 6% like for like* following an exceptional first quarter.

As expected, operating margin on ordinary activities rose substantially, up 150bp from 12.5% to 14.0%. Operating profit from ordinary activities amounted to ?8.5 million, a 23% increase over the same period in 2009.

These excellent performances are proof that Cegedim’s range of software (Activ’Infinite) and services (various data flow management platforms) is well suited to a rapidly evolving health insurance sector, in which differentiation and productivity gains are crucial.

It is also worth noting the robust trend in the sales of Cegedim SRH, which specializes in the services associated with outsourcing payroll and HR management. Its revenues rose by more than 12% in the first half of 2010, and its profitability improved.

Financial resources

At June 30, 2010, Cegedim’s consolidated total balance sheet amounted to ?1,535 billion, a 15.6% jump over the year-earlier period.

The Group has a robust balance sheet position, with share capital representing 37% of total asset, a 20% increase.

Acquisition goodwill was ?713 million, compared with ?613 million at the end of 2009. This represents 46% of the total balance sheet, which is the same level as six months prior. These trends are attributable chiefly to currency exchange rate and acquisitions.

Cash and equivalents exceed short-term financial debt (less than 1 year).

Netfinancial debt amount to ?443 million compared with ?395 million six months earlier. As expected this increase is due to the use of Cegedim credit revolver facility in order to finance ac quisitions and to the negative evolution of the dollar against the euro.

After the net cost of financial debt and taxes, cash flow was ?51.4 million, on a par with that of the first half of 2009. Gearing level remains unchanged at 0.9 against 0.8 six months earlier.

Working capital requirement increased by ?6.6 million, mainly due to the change in customer receivables. These trends reflect seasonal effects on the Group’s working capital requirement.

At the end of June 2010, the Group complied with all its bank covenants.

First-half highlights

On January 7, 2010, the Group acquired US company SK&A Information Services, Inc., a top-notch supplier of healthcare data. The acquisition strengthens Cegedim’s OneKey offering in the US. Created 26 years ago, SK&A has built and maintains a database with targeted information on more than 2 million healthcare professionals, including more than 800,000 prescribing physicians. This is the only database of US prescribing physicians and other healthcare professionals for which every single email address has been verified by phone contact. The acquired businesses generate full-year revenues of roughly $15 million. Its operational and commercial integration, which was completed in less than 6 months, was a complete success.

On June 3, 2010, Cegedim finalized the acquisition of Swiss CRM and direct marketing businesses from IMS Health to complement and strengthen its existing Swiss offerings. The CRM and Direct Marketing Direct business unit of IMS Health GmbH has been targeting the life science industry in Switzerland for more than a decade and is recognized for its quality and reliability by more than 500 users and 30 companies. The acquired businesses will contribute to the Group’s consolidated result from Q2 2010. Cegedim expects the acquired company to contribute annual revenues in the region of ?2 million.

Moreover, the Group announced on June 18, 2010 the acquisition of French company Hosta, a specialist in third-party management in which it has held a minority stake since 2004. Managing 400,000 beneficiaries and boasting extensive experience in third-party management of health and personal protection insurance policies, Hosta is among France’s leading third-party management companies. This acquisition expands Cegedim Group’s portfolio of solutions dedicated to all of its clients in the insurance sector. The acquired businesses represent annual revenues of approximately ?11 million.

These three deals were financed by internal financing and will not prevent the Group from respecting its debt covenants. Under the agreements signed by the parties, all other terms of the transactions are confidential.

Significant post-closing transactions and events

– Extension of the average maturity of the debt

As part of its policy of diversifying and extending the average maturity of its debt, Cegedim (BB+ S&P), completed on July 27 issuance of a ?300 million bond maturing in 2015, with a fixed annual coupon of 7.00% payable every six months. The strong demand generated by the operation, finalized in just half a day, the quality of the interested parties, and geographic diversity of the investors – of which 70% were located outside of France – enabled Cegedim to raise the ?300 million under favorable conditions. At the same time, the debt issue demonstrates Cegedim’s ability to tap financial markets.

– External growth

On July 27 Cegedim finalized the acquisition of Pulse Systems, Inc., a leading US healthcare software and services supplier. The move gives Cegedim access to the US market for the computerization of healthcare professionals at a very critical time for the Electronic Health Records (EHR) and Practice Management (PM) software markets.

Founded in 1997, Pulse Systems has developed an extremely sophisticated and scalable ambulatory healthcare IT solution – Pulse Patient Relationship Management. This solution includes EHR, PM, e-Prescribing, Revenue Cycle Management services, etc. The company is based in Wichita and has more than 100 employees. Pulse is profitable and will likely continue to grow in a rapidly expanding sector: it expects to increase its revenues more than four-fold by 2014.

Building on the Target Software acquisition in 2005, the Dendrite acquisition in 2007 and the SK&A acquisition earlier this year, this new addition in the US is squarely in line with the Group’s global strategy. It will enable the Group to leverage its complementary activities in North America and transform its European Cegedim Healthcare Software division into a global player by utilizing the Pulse solutions to expand its presence in the US market.

Cegedim finalized the acquisition of Deskom a leading French B-to-B invoice dematerialization company, on September 6th. The deal is an opportunity for Cegedim EDI, its professional electronic data management department, to build on its leadership in the field.

The Deskom acquisition allows Cegedim EDI, the healthcare data exchange leader, to move ahead with its strategy of opening its services to all business sectors and becoming Europe’s top electronic invoicing network, able to handle any request regardless of invoice volumes, project complexity, or the number of countries involved.

These activities represent annual revenues of around ?4 million and will be part of the consolidation scope of Cegedim Group for H2 2010.

These two deals were financed by internal financing. Under the agreements signed by the parties, all other terms of the transactions are confidential.

– New trademark strategy and visual identity for the Group

In order to strengthen its image, Cegedim Management decided to simplify the brand’s visual identity for the Group and its main healthcare Business Units. Each Business Unit’s logo and name will reflect a key description of its overall activity. Therefore, Cegedim Dendrite has been renamed Cegedim Relationship Management.

This change is inspired by the Group’s desire to present its customers with a more coherent, unified image of all of its businesses and to succinctly convey its commitment to providing them with the most advanced products and services in the industry. It is also a way of expressing the successful integration of Dendrite, as the new visual identity will incorporate some graphic elements from its logo.

These changes will take place gradually starting on September 24, 2010. An analysis of the possible accounting consequences of canceling the Dendrite trademark are still under way.

As part of its new brand strategy and to simplify and modernize this window on the Group, Cegedim will launch its new corporate website: www.cegedim.com This new, redesigned portal does more to emphasize the Group’s various activities and gives users direct access to the sites of its Business Units, while incorporating traditional sections on Recruitment, Press and Finance.

2010 outlook

Acquisitions made during the first half-year, as well as the post-closing acquisitions of Pulse and Deskom, are in line with the external growth policy the Group presented at the time of the December 2009 capital increase. These acquisitions did not prevent the Group from meeting all of its covenants. We recall that the sole purpose of the bond issue for ?300 million on July 27, 2010, was to refinance existing bank debt.

Given its adaptability, good regional mix and business mix of revenues, commercial momentum and half-year performances, the Group confirms its goal to consolidate leadership in the global healthcare market with revenue growth of approximately 5% for 2010

Based on its half-year results, the Group is no longer aiming for margin improvement for 2010.

Financial calendar

+-------------------------+--------------------+--------------------+
|The Group will hold a    |                    |                    |
|conference call this     |                    |                    |
|evening (September 23) at|                    |                    |
|6:15 pm in French and    |                    |                    |
|7:00 pm in English at the|                    |                    |
|following numbers (Paris |                    |                    |
|time):                   |                    |                    |
+-------------------------+--------------------+--------------------+
|                         |· From France: 01 72|Access code:        |
|                         |30 02 03            |13648531            |
+-------------------------+--------------------+--------------------+
|                         |· From UK: 1616 018 |#                   |
|                         |915                 |                    |
+-------------------------+--------------------+--------------------+
|                         |· From the US: 703  |                    |
|                         |62 19 122           |                    |
+-------------------------+--------------------+--------------------+
+-------------------------+--------------------+--------------------+

September 24, 2010

– SFAF Meeting – 24 rue de Penthièvre 75008 Paris (at 10:00am)

– Half-year Financial Report (after the stock market closes)

From September 27 to October 15, 2010

– Roadshow in Europe

From October 4 to October 8, 2010

– Roadshow in the US

November 15, 2010

– Q3 revenues announcement (after the stock market closes)

Additional information

The Board of Directors and the Auditors met on September 23, 2010, to approve 2010 Half-year consolidated financial statements. Audit procedures have been performed and the 2010 Half-year statutory auditors’ report on the consolidated financial statements is forthcoming.

The financial information presented in this press release comes from Cegedim half year consolidated financial statements and is fully available on the 2010 Half-year Financial Report at www.cegedim.fr/finance as of September 24, 2010.

A presentation of Cegedim 2010 Half-year results is also available on the Website.

Appendices

– Revenues by sector and by quarter#:

# Figures rounded to the nearest unit.

Year 2010

+-------------------------+---------+---------+----+----+---------+
|? thousands              |    Q1   |    Q2   |  Q3|  Q4|   Total |
+-------------------------+---------+---------+----+----+---------+
|CRM and strategic data   |  111,532|  137,575|    |    |  249,107|
+-------------------------+---------+---------+----+----+---------+
| Healthcare professionals|   64,461|   74,278|    |    |  138,739|
+-------------------------+---------+---------+----+----+---------+
|Insurance and services   |   29,627|   31,364|    |    |   60,991|
+-------------------------+---------+---------+----+----+---------+
|Group                    |  205,620|  243,217|    |    |  448,837|
+-------------------------+---------+---------+----+----+---------+
+-------------------------+---------+---------+----+----+---------+

Year 2009 pro-forma

For information, Revenues at June 30, 2009 were restated between sectors for an amount of ?4.4 million. In order to continue streamlining the Group’s structure, certain activities of the Healthcare professionals and Insurance and services sectors have been linked to entities of the CRM and strategic data sector. Pro-forma revenue is mentioned below.

+-------------------------+---------+---------+---------+---------+---------+
|? thousands              |    Q1   |    Q2   |    Q3   |    Q4   |   Total |
+-------------------------+---------+---------+---------+---------+---------+
|CRM and strategic data   |  117,523|  123,223|  117,178|  140,361|  498,285|
+-------------------------+---------+---------+---------+---------+---------+
| Healthcare professionals|   65,247|   72,411|   58,779|   67,817|  264,254|
+-------------------------+---------+---------+---------+---------+---------+
|Insurance and services   |   25,892|   29,609|   22,062|   33,970|  111,533|
+-------------------------+---------+---------+---------+---------+---------+
|Group                    |  208,662|  225,245|  198,017|  242,148|  874,072|
+-------------------------+---------+---------+---------+---------+---------+
+-------------------------+---------+---------+---------+---------+---------+

– By sector of activity and currency, the distribution of revenues for the first half-year of 2010 is as follows:

+-------------------------+------+-----+-----+--------+
|                         |  Euro|  USD|  GBP|  Others|
+-------------------------+------+-----+-----+--------+
|CRM and strategic data   |   51%|  23%|   4%|     22%|
+-------------------------+------+-----+-----+--------+
| Healthcare professionals|   80%|    -|  20%|       -|
+-------------------------+------+-----+-----+--------+
|Insurance and services   |   99%|    -|    -|      1%|
+-------------------------+------+-----+-----+--------+
|Group                    |   66%|  13%|   9%|     12%|
+-------------------------+------+-----+-----+--------+
+-------------------------+------+-----+-----+--------+

– By sector of activity and geographic zone, the distribution of revenues for the first half-year of 2010 is as follows:

+-------------------------+--------+------------------+---------------+
|                         |  France|  Europe ex France|  North America|
+-------------------------+--------+------------------+---------------+
|CRM and strategic data   |     31%|               33%|            24%|
+-------------------------+--------+------------------+---------------+
| Healthcare professionals|     77%|               23%|              -|
+-------------------------+--------+------------------+---------------+
|Insurance and services   |     99%|                 -|              -|
+-------------------------+--------+------------------+---------------+
|Group                    |     55%|               26%|            13%|
+-------------------------+--------+------------------+---------------+
+-------------------------+--------+------------------+---------------+

+-------------------------+-------------------+
|                         |  Rest of the world|
+-------------------------+-------------------+
|CRM and strategic data   |                12%|
+-------------------------+-------------------+
| Healthcare professionals|                  -|
+-------------------------+-------------------+
|Insurance and services   |                 1%|
+-------------------------+-------------------+
|Group                    |                 7%|
+-------------------------+-------------------+
+-------------------------+-------------------+

– Consolidated first-half financial statements

Assets

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Goodwill on acquisition  |     713,179|     613,342|
+-------------------------+------------+------------+
|Development costs        |      31,057|      57,644|
+-------------------------+------------+------------+
|Trademarks, patents      |     135,868|     104,810|
+-------------------------+------------+------------+
|Other intangible fixed   |     106,145|      63,192|
|assets                   |            |            |
+-------------------------+------------+------------+
|Intangible fixed assets  |     273,070|     225,646|
+-------------------------+------------+------------+
|Property                 |         446|         417|
+-------------------------+------------+------------+
|Buildings                |       6,168|       6,225|
+-------------------------+------------+------------+
|Plant, machinery and     |      24,940|      24,377|
|equipment                |            |            |
+-------------------------+------------+------------+
|Other tangible fixed     |      13,866|      13,969|
|assets                   |            |            |
+-------------------------+------------+------------+
|Construction work in     |          35|         234|
|progress                 |            |            |
+-------------------------+------------+------------+
|Tangible fixed assets    |      45,456|      45,221|
+-------------------------+------------+------------+
|Equity investments       |         295|         302|
+-------------------------+------------+------------+
|Loans                    |         555|         551|
+-------------------------+------------+------------+
|Other fixed financial    |       9,103|       8,030|
|assets                   |            |            |
+-------------------------+------------+------------+
|Fixed financial assets ? |       9,953|       8,883|
|excluding shares of      |            |            |
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Shares of                |       6,811|       7,173|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Government ? Deferred tax|      42,476|      33,350|
+-------------------------+------------+------------+
|Accounts receivable:     |      16,056|      15,282|
|long-term portion        |            |            |
+-------------------------+------------+------------+
|Other receivables:       |       2,064|         983|
|long-term portion        |            |            |
+-------------------------+------------+------------+
|Non-current assets       |   1,109,064|     949,881|
+-------------------------+------------+------------+
|Services in progress     |         188|         200|
+-------------------------+------------+------------+
|Goods                    |      11,005|      10,956|
+-------------------------+------------+------------+
|Advances and deposits    |       1,882|       1,172|
|received on orders       |            |            |
+-------------------------+------------+------------+
|Accounts receivable:     |     226,488|     210,502|
|short-term portion       |            |            |
+-------------------------+------------+------------+
|Unpaid, called-up capital|           -|           -|
+-------------------------+------------+------------+
|Other receivables:       |      20,533|      18,413|
|short-term portion       |            |            |
+-------------------------+------------+------------+
|Cash equivalents         |       1,159|      30,630|
+-------------------------+------------+------------+
|Cash                     |     141,814|      90,739|
+-------------------------+------------+------------+
|Prepaid expenses         |      22,936|      15,847|
+-------------------------+------------+------------+
|Current assets           |     426,006|     378,461|
+-------------------------+------------+------------+
|Total assets             |   1,535,070|   1,328,341|
+-------------------------+------------+------------+

Liabilities

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Share capital            |      13,337|      13,337|
+-------------------------+------------+------------+
|Issue premium            |     185,562|     185,562|
+-------------------------+------------+------------+
|Group reserves           |     294,967|     249,732|
+-------------------------+------------+------------+
|Group translation        |        -238|        -238|
|reserves                 |            |            |
+-------------------------+------------+------------+
|Group translation        |      46,317|     -37,844|
|gains/losses             |            |            |
+-------------------------+------------+------------+
|Group earnings           |      19,849|      54,719|
+-------------------------+------------+------------+
|Investment subsidies     |           -|           -|
+-------------------------+------------+------------+
|Regulated provisions     |           -|           -|
+-------------------------+------------+------------+
|Shareholders? equity,    |     559,794|     465,267|
|Group share              |            |            |
+-------------------------+------------+------------+
|Minority interests       |         383|         609|
|(reserves)               |            |            |
+-------------------------+------------+------------+
|Minority interests       |          72|         114|
|(earnings)               |            |            |
+-------------------------+------------+------------+
|Minority interests       |         455|         724|
+-------------------------+------------+------------+
|Shareholders? equity     |     560,249|     465,991|
+-------------------------+------------+------------+
|Long-term financial      |     453,067|     391,408|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Long-term financial      |      10,707|      16,517|
|instruments              |            |            |
+-------------------------+------------+------------+
|Deferred tax liabilities |      60,298|      51,394|
+-------------------------+------------+------------+
|Non-current provisions   |      28,534|      21,517|
+-------------------------+------------+------------+
|Other non-current        |      12,396|       9,550|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Non-current liabilities  |     565,002|     490,386|
+-------------------------+------------+------------+
|Short-term financial     |     142,671|     133,621|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Short -term financial    |           -|           -|
|instruments              |            |            |
+-------------------------+------------+------------+
|Accounts payable and     |      71,813|      73,604|
|related accounts         |            |            |
+-------------------------+------------+------------+
|Tax and social           |     119,088|     113,705|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Provisions               |       6,116|       7,133|
+-------------------------+------------+------------+
|Other current liabilities|      70,131|      43,902|
+-------------------------+------------+------------+
|Current liabilities      |     409,819|     371,965|
+-------------------------+------------+------------+
|Total liabilities        |   1,535,070|   1,328,341|
+-------------------------+------------+------------+

– Income statement

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Revenues                 |     448,837|     433,906|
+-------------------------+------------+------------+
|Other income from        |           -|           -|
|business activities      |            |            |
+-------------------------+------------+------------+
|Capitalized production   |      15,186|      16,616|
+-------------------------+------------+------------+
|Purchased consumed       |     -48,637|     -47,729|
+-------------------------+------------+------------+
|External expenses        |    -110,205|    -106,409|
+-------------------------+------------+------------+
|Taxes                    |      -7,069|      -6,503|
+-------------------------+------------+------------+
|Payroll costs            |    -213,954|    -201,391|
+-------------------------+------------+------------+
|Depreciation expenses    |     -33,494|     -34,179|
+-------------------------+------------+------------+
|Provision expenses and   |         -69|         391|
|write-backs              |            |            |
+-------------------------+------------+------------+
|Change in inventories of |         -20|         -63|
|in-progress and finished |            |            |
|products                 |            |            |
+-------------------------+------------+------------+
|Other operating income   |          49|        -560|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Operating profit from    |      50,624|      54,079|
|ordinary activities      |            |            |
+-------------------------+------------+------------+
|Other non-current        |      -5,448|      -4,657|
|operating income and     |            |            |
|expenses                 |            |            |
+-------------------------+------------+------------+
|Operating profit         |      45,175|      49,422|
+-------------------------+------------+------------+
|Income from cash and cash|         564|         829|
|equivalents              |            |            |
+-------------------------+------------+------------+
|Gross cost of financial  |     -12,283|     -20,304|
|debt                     |            |            |
+-------------------------+------------+------------+
|Other financial income   |      -9,866|     -10,349|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Net cost of financial    |     -21,585|     -29,824|
|debt                     |            |            |
+-------------------------+------------+------------+
|Income taxes             |     -16,134|      -3,005|
+-------------------------+------------+------------+
|Deferred income taxes    |      12,069|         279|
+-------------------------+------------+------------+
|Tax expenses             |      -4,065|      -2,726|
+-------------------------+------------+------------+
|Share of earnings of     |         396|         368|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Consolidated net profit  |      19,921|      17,240|
+-------------------------+------------+------------+
|Group share (A)          |      19,849|      17,237|
+-------------------------+------------+------------+
|Minority interests       |          72|           3|
+-------------------------+------------+------------+
|Average number of shares |  13,963,775|   9,331,449|
|excl. Treasury stocks (B)|            |            |
+-------------------------+------------+------------+
|Earnings per share -     |         1.4|         1.8|
|euros (A/B)              |            |            |
+-------------------------+------------+------------+
|Dilutive instruments     |           -|           -|
+-------------------------+------------+------------+
|Diluted earnings per     |         1.4|         1.8|
|share - euros            |            |            |
+-------------------------+------------+------------+

– Cash flow statement

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Consolidated net profit  |      19,921|      17,240|
+-------------------------+------------+------------+
|Share of earnings of     |        -396|        -368|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Depreciation and         |      31,885|      34,411|
|amortization expense     |            |            |
+-------------------------+------------+------------+
|Capital gain or losses on|         -33|         275|
|disposals                |            |            |
+-------------------------+------------+------------+
|Cash flow after net cost |      51,377|      51,558|
|of financial debt and    |            |            |
|taxes                    |            |            |
+-------------------------+------------+------------+
|Net cost of financial    |      21,585|      29,824|
|debt                     |            |            |
+-------------------------+------------+------------+
|Tax expenses             |       4,065|       2,726|
+-------------------------+------------+------------+
|Cash flow before net cost|      77,027|      84,108|
|of financial debt and    |            |            |
|taxes                    |            |            |
+-------------------------+------------+------------+
|Tax paid                 |      -9,368|         245|
+-------------------------+------------+------------+
|Plus: change in operating|     -17,759|     -11,179|
|working capital          |            |            |
|requirement              |            |            |
+-------------------------+------------+------------+
|Net cash from operations |      49,900|      73,174|
|(A)                      |            |            |
+-------------------------+------------+------------+
|Acquisitions of          |     -18,160|     -20,044|
|intangible fixed assets  |            |            |
+-------------------------+------------+------------+
|Acquisitions of tangible |     -13,045|     -12,098|
|fixed assets             |            |            |
+-------------------------+------------+------------+
|Acquisitions of financial|           -|      -1,454|
|assets                   |            |            |
+-------------------------+------------+------------+
|Disposals of tangible and|       2,074|       2,263|
|intangible fixed assets  |            |            |
+-------------------------+------------+------------+
|Disposals of financial   |         124|         363|
|assets                   |            |            |
+-------------------------+------------+------------+
|Impact of changes in     |     -25,680|      -2,691|
|consolidation scope      |            |            |
+-------------------------+------------+------------+
|Dividends from equity    |           -|           -|
|accounted affiliates     |            |            |
+-------------------------+------------+------------+
|Net cash from investment |     -54,687|     -33,661|
|operations (B)           |            |            |
+-------------------------+------------+------------+
|Dividends paid to parent |           -|           -|
|company shareholders     |            |            |
+-------------------------+------------+------------+
|Dividends paid to the    |           -|           -|
|minority interests of    |            |            |
|consolidated companies   |            |            |
+-------------------------+------------+------------+
|Increase in cash capital |           -|           -|
+-------------------------+------------+------------+
|Debt issued              |      61,611|      62,240|
+-------------------------+------------+------------+
|Debt reimbursements      |     -57,587|     -86,091|
+-------------------------+------------+------------+
|Interest paid on debts   |     -10,606|     -21,435|
+-------------------------+------------+------------+
|Other financial income   |      -8,073|      -2,675|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Net cash from financing  |     -14,655|     -47,961|
|operations ©           |            |            |
+-------------------------+------------+------------+
|Change in cash (A+B+C)   |     -19,442|      -8,448|
+-------------------------+------------+------------+
|Opening cash position    |     102,338|      70,254|
+-------------------------+------------+------------+
|Closing cash position    |      89,379|      61,539|
+-------------------------+------------+------------+
|Foreign exchange gains or|      -6,483|         267|
|losses                   |            |            |
+-------------------------+------------+------------+

*at constant scope and exchange rates

About Cegedim: Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of ?874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com

Contacts:

+--+--------------------+--------------------+--------------------+--+
|  |     Aude BALLEYDIER|Jan Eryk UMIASTOWSKI|Guillaume DE        |  |
|  |                    |                    |CHAMISSO            |  |
+--+--------------------+--------------------+--------------------+--+
|  |             Cegedim|             Cegedim|Presse & Papiers    |  |
|  |                    |                    |Agency              |  |
+--+--------------------+--------------------+--------------------+--+
|  |     Media Relations|Chief investment    |       Press Officer|  |
|  |                    |Officer Investor    |                    |  |
|  |                    |Relations           |                    |  |
+--+--------------------+--------------------+--------------------+--+
|  |                    |Tel.: +33 (0)1 49 09|                    |  |
|  |                    |33 36               |                    |  |
+--+--------------------+--------------------+--------------------+--+
|  |Tel.: +33 (0)1 49 09|investor.relations@c|Tel.: +33 (0)1 77 35|  |
|  |68 81               |egedim.fr           |60 99               |  |
+--+--------------------+--------------------+--------------------+--+
|  |aude.balleydier@cege|                    |guilaume.dechamisso@|  |
|  |dim.fr              |                    |pressepapiers.fr    |  |
+--+--------------------+--------------------+--------------------+--+
+--+--------------------+--------------------+--------------------+--+

This information is provided by HUGIN

LAS VEGAS, NV–(Marketwire – September 22, 2010) –  Medex, Inc. (PINKSHEETS: MDXX), today announced four strategic hires and several facilities expansions intended to foster significant revenue and earnings growth at the Company’s Creative Rehab Technology Services, Inc. and Bee Mobile, Inc. operations.

Kia Davis, 35, has been appointed service coordinator for Creative Rehab and will be based in that company’s newly relocated and expanded facility in Rancho Cucamonga, California. Davis will be responsible for new business development in the greater Los Angeles area as well as contracts management with a growing dealer network there and throughout the Inland Empire.

Additionally, Michael Spradley, 40, has been hired as a seating and mobility specialist. With significant industry contacts and related sales experience, he will be supported by two additional technician hires in San Diego and Escondido, California. These individuals will support sales at Creative Rehab and servicing contracts for Bee Mobile.

In related matters, Medex indicated that facility expansions are in progress at Creative Rehab’s headquarters in Chula Vista, California and that Bee Mobile, in addition to the above referenced Rancho Cucamonga relocation, has acquired an additional 5,000 square foot repair and warehouse facility in Fontana, California to improve efficiency and output of its capacities.

Medex also indicated that Bee Mobile is currently finalizing contractual arrangements with several dealers in the greater Las Vegas area to provide services and repair.

“Growth in demand for products and service necessitate capital investment for both plant infrastructure as well as key personnel. We anticipate that this investment should yield a 30% revenue growth for both companies combined with previously disclosed corresponding cumulative net margin improvement,” said Paul Protzman, President of Medex, Inc. “We are encouraged by current market response to these business lines.”

About Medex, Inc.

Medex, Inc. is a development stage Nevada-based medical support services company, which plans to grow through acquisitions of medical supply companies, medical technology companies, and assisted living and care facilities worldwide. For additional information, see www.medexsynergies.com.

Safe Harbor Statement:

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

CHICAGO, IL–(Marketwire – September 22, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) www.ForceLogix.com (the “Company“) announced today that effective September 22, 2010, 340,216 common shares were issued to an Insider (as that term is defined in Exchange Policy 1.1) upon conversion of certain special warrants originally issued to holders at the closing of the Company’s Qualifying Transaction on November 30, 2009. Following issuance of said common shares, the Company has 61,202,615 common shares and 22,552,060 non-exercised special warrants outstanding. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

CLIFTON, NJ–(Marketwire – September 22, 2010) –  Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a leading provider of a broad line of electronic security system technologies to the government and private sectors, announced financial results for the fiscal year ended June 30, 2010.

Arthur Barchenko, President and CEO, stated, “We achieved our objective during fiscal 2010 to change the direction of the Company’s marketing effort from that of a prime contractor to the Department of Defense to that of a technology manufacturing resource and support service provider to the large system integrators, dealers/installers and, in certain cases, the end user i.e. nuclear power stations.

“To that end, we achieved net revenues of $4,513,737 for fiscal year 2010 as compared to $3,472,696 for fiscal year 2009, representing an increase of approximately 30%. The increase in net revenues during 2010 as compared to 2009 is attributable equally to increases in both government and private-sector related purchase orders.”

Gross margins for 2010 were 55% as compared to 28% of revenue for the 2009 Period. The increase in gross margin for the fiscal year ended June 30, 2010 compared to the corresponding period in 2009 is primarily attributable to a change in the order mix of equipment sales and support services. We experienced an increase in both higher margin equipment sales as well as design and engineering support service billings which, combined, resulted in the increase in gross margins for the Fiscal 2010 Period.

Selling, general and administrative expenses increased approximately 34% in the 2010 Period to $1,771,923 from $1,318,910 in 2009. The increase is partially attributable to costs relating to the U.N. project in Ethiopia where we incurred significant increases in freight and marketing related expenses. However, the major increase in costs related to management’s decision to recognize and write off certain receivables totaling $629,437 related to two overseas projects in Asia and the Middle East and uncollectible Department of Defense (DoD) program-related expenses. Although we attempted to resolve these issues during the past year, we have not been able to collect these receivables. Based on these results, management has made the decision not to seek the award of DoD prime contracts in the future. 

Mr. Barchenko stated that, “I am also pleased to announce that, on July 30, 2010, the Company paid off the principal balance of $100,000 plus interest completing its short and long-term convertible principal debt obligations.

“During fiscal 2010, the Company submitted proposals on projects for Department of Defense facilities and certain nuclear power stations in the United States and southeast Asia valued at approximately $13,650,000. A number of these DoD and nuclear projects amounting to $2.2 million was awarded and partially shipped during the fourth quarter of fiscal 2010. Most of these proposals are still pending and awaiting approval, funding and award. We anticipate decisions relating to these remaining proposals within the first half of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 and the first half of fiscal 2012.”

About ECSI

ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high profile, high threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, legislative or regulatory changes that affect us, the availability of working capital, timing of purchase orders, acceptance of company proposals, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, changes in our acquisition and capital expenditure plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

BETHESDA, MD–(Marketwire – September 21, 2010) –  Coventry Health Care, Inc. (NYSE: CVH) announced today that it will release third quarter 2010 financial results on Friday, November 5, 2010. Allen Wise, Coventry’s Chief Executive Officer, will be hosting a conference call at 8:30 a.m. ET on that day. To listen to the call, dial toll-free at (877) 591-4959 or, for international callers, (719) 325-4748. Callers will be asked to identify themselves and their affiliations. 

The conference call will also be webcast from Coventry’s Investor Relations website at www.coventryhealthcare.com. Coventry asks participants on both the call and webcast to review and be familiar with its Securities and Exchange Commission filings. A replay of the call will be available for one week at (888) 203-1112 or, for international callers, (719) 457-0820. The access code is 5680841.

Coventry Health Care (www.coventryhealthcare.com) is a diversified national managed healthcare company based in Bethesda, Maryland, operating health plans, insurance companies, network rental and workers’ compensation services companies.  Coventry provides a full range of risk and fee-based managed care products and services to a broad cross section of individuals, employer and government-funded groups, government agencies, and other insurance carriers and administrators. 

SAN FRANCISCO, CA–(Marketwire – September 21, 2010) –  Rothman Healthcare Corporation (Rothman) today announced the appointment of Richard Sommer as Chief Executive Officer. “Richard is a natural fit for our company because he shares our passion for leveraging the new digital infrastructure in medicine to save lives and lower costs and because of his strong track record and background in healthcare information technology,” said Michael Rothman Ph.D., Co-Founder and Chief Science Officer. “We’ve spent over six years researching and developing our product and with Richard’s proven leadership, we can bring Rothman Healthcare into a burgeoning marketplace seeking true ‘meaningful use’ tools.”

Mr. Sommer has over 20 years of executive experience with 12 in the field of healthcare. He served as Co-Founder and CEO of De La Cruz Occupational Healthcare, Inc. and Medchannel, Inc., Chairman of the Committee for Hospital and Provider Reimbursements for the State of California, and Healthcare Economist for the State of California. As a seven-time CEO of both public and private companies, Mr. Sommer has demonstrated the ability to create strong profitable growth, substantially increase shareholder value, and bring revolutionary technologies to the marketplace. While CEO of HomeGain.com, Mr. Sommer grew revenues 250% and led the sale of the company for 29 times earnings, creating over $108 million in shareholder value. While at De La Cruz, Mr. Sommer grew revenues and earnings for ten consecutive years between 30-100% annually.

“Rothman has a long-standing commitment to improving patient care,” said Dr. G. Duncan Finlay, Chief Medical Officer and former CEO of Sarasota Memorial Hospital. “Richard understands our mission, our market and how to bring Rothman’s product to caregivers across the country.”

“I am excited to work with Rothman Healthcare,” said Sommer. “It combines my expertise in healthcare and my experience of growing promising companies with big ideas into big market players. Rothman’s technology has the potential to revolutionize the practice of medicine. I want to be a part of that paradigm shift.”

About Rothman Healthcare Corporation

Since 2004, Rothman Healthcare Corporation has been developing the Patient Condition Tracker to bridge gaps in continuity of care. Rothman’s software application uses electronic health record (EHR) data to highlight subtle declines in patient health and alert physicians in snapshot form. Rothman’s software application draws data from a hospital’s EHR system to generate and display a health score based on vital signs, nursing assessments and lab results, in a user-friendly and color-coded graphical format. The software allows clinicians to more easily understand patient conditions, offering the ability to see multiple patient graphs simultaneously for a high-level overview of a whole unit.

Rothman Healthcare Corporation is committed to improving quality and efficiency in patient care through innovative, patient-centric software enabling healthcare professionals to easily access critical and actionable patient health data. For more information, visit www.rothmanhealthcare.com.

NEW YORK, NY–(Marketwire – September 21, 2010) –  Emmy award-winning actress Claire Danes joined millions of people who’ve added their thumbprints to a unique petition at Grand Central Terminal, led by global humanitarian organisation Save the Children.

For downloadable photos, video and other supporting documents please visit: http://www.multimedianewscenter.com/savethechildren/three-million-give-thumbs-up-to-saving-childrens-lives

The thumbprint mosaic was designed by New York-based artist Ian Wright and represents the support of three million people from 40 countries who have taken part in Save the Children’s EVERY ONE campaign. The campaign aims to put pressure on world leaders meeting at the United Nations in New York, to do more to stop children dying needlessly of preventable and treatable causes.

The thumbprints will be handed over to a high level representative of the United Nations during the summit this week to review progress on the Millennium Development Goals, the internationally agreed targets to tackle poverty. Save the Children is calling for an action plan to be agreed to by all governments, to reach the Millennium Goal of cutting child deaths by two thirds by 2015. Hitting this target would save the lives of 15 million children by 2015, the charity said. It would involve improving children’s access to basic health care, nutrition, water and sanitation and education.

For more information, please visit www.everyone.org for the global EVERY ONE campaign and www.goodgoes.org in the U.S.

Click here http://www.multimedianewscenter.com/savethechildren/three-million-give-thumbs-up-to-saving-childrens-lives for access to:

• Footage of NYC Unveil Event
• Visuals of the Thumbprint Installation
• Photos of Emmy Award-Winning Actress Claire Danes
• B-roll of Claire adding her thumbprint
• Photos and B-roll of visual petition
• Soundbites w/ Emmy Award-Winning Actress Claire Danes
• Soundbites w/ Jasmine Whitbread, CEO, Save the Children International
• Other supporting documents and photos

TUCSON, AZ–(Marketwire – September 20, 2010) –  Travel + Leisure has revealed its Top Ten Destination Spas (World’s Best Awards 2010) and Canyon Ranch is thrilled to announce it has received this highly coveted accolade. Resort properties in Tucson and Lenox are once again joining the ranks, and Canyon Ranch Hotel & Spa in Miami Beach is making its debut.

The “World’s Best Awards” are voted on by the readers of Travel + Leisure to honor the top hotels, destinations, airlines, cruises, spas and transportation companies in the world. In the annual survey, destination spas were rated independently by Travel + Leisure readers in five categories: accommodations/ambiance, treatments, service, food and value. The Top Ten Destination Spas will be featured in the October issue of Travel + Leisure magazine (on newsstands September 24) and on www.travelandleisure.com.

“We couldn’t be happier to see three of our properties listed in the World’s Best Awards by the well-traveled readers of Travel + Leisure,” said Jerry Cohen, Canyon Ranch Vice Chair and CEO. “This recognition reflects our continued dedication to creating an environment that promotes health and the highest enjoyment of life for all of our guests.”

As a newcomer to the list, Canyon Ranch Hotel & Spa in Miami Beach, which opened in November 2008, has quickly established itself as a top hotel for the healthful minded traveler. Canyon Ranch Hotel & Spa in Miami Beach provides its guests with an integrative approach to health and wellness in order to create a life-enhancing transformation while also delivering a complete luxurious travel experience and world class spa.

“Canyon Ranch was founded 31 years ago with a mission to inspire people to make a commitment to healthy living,” said Cohen. “Whether our guests choose to experience Canyon Ranch in Tucson, Lenox or Miami Beach, they know they will receive the same personalized attention — it’s the Canyon Ranch way of life.”

About Canyon Ranch
Canyon Ranch pioneered the evolution of wellness lifestyle and has been an industry leader for 30 years. Operating the world’s most celebrated collection of life-enhancement properties, Canyon Ranch has destination health resorts in Tucson, Ariz., Lenox Mass., and recently opened Canyon Ranch Hotel & Spa in Miami Beach, the nation’s first luxury wellness hotel and residential community. In addition, Canyon Ranch operates SpaClub facilities (spa, wellness and fitness facilities designed to give guests a taste of the more intensive resort experiences) at The Venetian & The Palazzo in Las Vegas, Nev. and the newest Canyon Ranch venture, Canyon Ranch SpaClub at Sea, features facilities onboard ships that make up Oceania Cruises and Regent Seven Seas Cruises, as well as on board Cunards’ Queen Mary 2 luxury ocean liner. In addition, the company Canyon Ranch has been named the “Healthiest Spa in America” by Health magazine as well as the “Best Spa for Food” by Gourmet magazine. Also, Canyon Ranch is the only 11-time recipient of the Condé Nast Traveler Best Destination Spa Award.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – September 17, 2010) – Save the Children experts attending the summit can discuss the following and more:

• How the MDGs affect everybody–even those who’ve never heard of them.
• What’s happening on the ground in the race to achieve the MDGs by 2015.
• How the MDGs have been incredibly successful in some of the poorest countries on earth–and what’s preventing them from being achieved elsewhere.
• Why U.N. Secretary General Ban Ki­moon will ask the world to focus on MDGs 4 and 5 (reducing child and maternal mortality), and what that’s likely to achieve.
• How the launch of a new nutrition movement could save 2.7 million children a year.
• How the U.S. role in global development could change in the years to come.

Charles MacCormack, President and CEO of Save the Children USA
Dr. Charles MacCormack is a senior statesman among leaders of U.S. development and humanitarian organizations. He has been president of Save the Children USA since 1993 and joined its board in 1989. Save the Children is the leading independent organization for children in need, with programs in 120 countries, including the United States. The agency works for immediate and lasting change in children’s lives by improving their health, education and economic opportunities. In times of acute crisis, Save the Children mobilizes rapid assistance to help children recover from the effects of war, conflict and natural disasters.

Anne M. Mulcahy, Chairman of the Board of Trustees, Save the Children USA; Former Chairman and CEO, Xerox Corporation
Anne Mulcahy saved Xerox and now she’s saving children. She became Chairman of Save the Children in March, 2010, after retiring as CEO of Xerox. One of the few women to lead a Fortune 500 company, she executed a dramatic turnaround at Xerox, lifting the corporation from threat of bankruptcy and putting it back on a profitable path. She’s recently visited Save the Children programs in Haiti, Guatemala and Afghanistan.

Ambassador Michael Klosson, VP for Policy and Humanitarian Response, Save the Children USA
Ambassador Michael Klosson draws on decades as a U.S. diplomat to advocate for children. He oversees Save the Children’s public policy and advocacy work with the U.S. and foreign governments around issues including health, education, food security, emergencies, and aid effectiveness. He also leads Save the Children’s emergency response work, including in Pakistan and Haiti.

Mary Beth Powers, Chief, Newborn & Child Survival Campaign, Save the Children USA
 Mary Beth Powers leads a campaign to bring lifesaving care to children in need. Save the Children’s “Seewherethegood goes™” campaign mobilizes citizen action to help local health workers help save more children worldwide. Powers is passionate about the power of training people in their own communities to provide better health opportunities for newborns and children around the world. See videos and blogs from these frontline workers at GoodGoes.org.

Carolyn Miles, Executive Vice President and Chief Operating Officer, Save the Children USA
Carolyn Miles manages all aspects of the global operations of Save the Children USA. She recently returned from Pakistan, where Save the Children has a major humanitarian response to the floods. Other recent trips to the field include Bangladesh and Haiti. Before joining Save the Children in 1998, she was an executive at American Express and a successful private entrepreneur in Hong Kong.

Dr. Rajiv Tandon, Sr. Advisor, Maternal, Newborn, Child Health and Nutrition, Save the Children India
Dr. Tandon works to save children’s lives in India, where more die than anywhere else. One fifth of the 8.1 million newborns and children who die before age 5 each year live in India. Most of those 1.7 million children die from preventable causes. Dr. Tandon is a pediatrician and public health expert with 25 years experience in child health and nutrition.

id=”nav_links”>

LAS VEGAS, NV–(Marketwire – September 17, 2010) – Medex, Inc. (PINKSHEETS: MDXX) today announced that on September 27, 2010 the Company will issue updated financials reflecting the closing of the previously announced Creative Rehab Technology Services, Inc. and Bee Mobile, Inc. acquisitions. Audited figures are expected to be consistent with previously disclosed revenue and earnings estimates and include those for the previously announced second Bee Mobile location which is now in operation.

In a related disclosure, Medex indicated that as of the close of the Company’s fourth quarter, December 31, 2010, Medex will commence routine scheduled quarterly earnings releases and investor conference calls. 

“Transparency is the foundation of investor confidence for any publicly held concern. As Medex energes from concept to reality and now perpares to accelerate its acquisition activity, routine financial disclosure is essential,” said Paul Protzman, President of Medex, Inc. “With newly acquired and growing revenue as well as free cash flow, the timing is now appropiate to begin this activity.”

About Medex, Inc.

Medex, Inc. is a development stage Nevada-based medical support services company, which plans to grow through acquisitions of medical supply companies, medical technology companies, and assisted living and care facilities worldwide. For additional information, see www.medexsynergies.com.  

Safe Harbor Statement:

This release contains “forward-looking statement” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

CALABASAS, CA–(Marketwire – September 15, 2010) – The McKenzie Institute has long been recognized as a leader in the professional development of physical therapists, especially in what has become known as the “McKenzie Method.” A recent partnership agreement with continuing education provider EDUCATA widens the scope of courses offered by the Institute to include EDUCATA’s interactive content, and exposes its own classes to the large number of EDUCATA members.

“Post-grad education for clinicians has been the cornerstone of our Institute since the mid 1950’s, when our highly-effective and evidence-based method of assessment, diagnosis and treatment for the spine and extremities was developed,” said Stacey Lyon, Executive Director of The McKenzie Institute USA. “Partnering with EDUCATA allows us to build on this foundation with additional courses that meet our standards of quality and boost our Mechanical Diagnosis and Therapy (MDT) Certification curriculum.”

“We are extremely proud of counting McKenzie among our partners,” said Dr. Marilyn Pink, EDUCATA President and CEO. “The Institute represents all that we value in the education of the therapist: a truly professional approach that delivers evidence-based content to PTs around the world.”

Under the terms of the agreement, EDUCATA courses will be accessed from the education channel at mckenziemdt.org and McKenzie courses will form part of EDUCATA’s catalog of offered classes.

About The McKenzie Institute: The McKenzie Institute USA, founded in 1982 as the first official branch and recognized as 501(c)3 not-for-profit, is one of 26 branches worldwide that train and certify physical therapists and other healthcare professionals through its multi-level educational curriculum. The Institute was proud to add an APTA and AAOMPT approved Fellowship Program in MDT in 2008.

About EDUCATA:  EDUCATA.COM is a unique, interactive, Web 2.0 education platform that delivers online learning. It offers a broad spectrum of courses from orthopaedics and pulmonology to geriatrics and oncology that are taught by top-ranked educators and experienced clinicians. EDUCATA’s partners include the World Confederation for Physical Therapy and many APTA chapters and sections. The company is a leader in providing continuing education for physical therapists and other medical professionals. 

Click here to see all recent news from this company

PITTSBURGH, PA–(Marketwire – September 15, 2010) –  Privately owned Deaf-Talk LLC dba DT Interpreting, the industry leader in on-demand video sign language interpreting, announced today that, pursuant to a stock exchange agreement, it has completed a reverse merger with Morgan Equities Group, Inc., a public company. Over ten-years old, DT Interpreting provides around the clock nationwide in-hospital interpreting services for the deaf. The newly merged company is named Deaf-Talk, Inc. and trades under the symbol (PINKSHEETS: MGQG). Deaf-Talk markets its services as DT Interpreting.

“DT Interpreting is the largest, fastest-growing company in its field with almost 400 hospital installations concentrated in the eastern and southern United States,” stated David Stauffer, executive vice president. “The company, which derives a large portion of its revenue from three-year contracts, now plans to market its services throughout the US southwest and entire western seaboard, with emphasis on California and Texas.”

DT Interpreting President, Robert Fisher, added: “The company attributes its leading market position to the integration of solid technology with certified sign language interpreters, which makes the communication between health care professionals and the deaf easy and timely. This is particularly important in emergencies when a few short minutes could be the difference between life and death.”

In addition to its video sign language interpreting, DT Interpreting also offers on-demand over-the-phone interpreting in more than 150 languages, full-scale document translation services and transcription into Braille.

More information about DT Interpreting can be found on the Company’s website: www.dtinterpreting.com.

About DT Interpreting
Founded in 1999 and now the industry leader, publicly-traded DT Interpreting is headquartered in Pittsburgh, PA with sales and customer service offices in Connecticut, Ohio and North Carolina. The Company provides on-demand video sign language and over the phone language interpretation, as well as full-scale document translation and translations into Braille.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Deaf Talk, Inc. dba DT Interpreting, which involves risks and uncertainties. The Company’s actual future results could materially differ from those discussed. The Company intends that such statements about the Company’s future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the “Safe Harbors” provision of the Private Securities Litigation Reform Act of 1995.

Click here to see all recent news from this company

PITTSBURGH, PA–(Marketwire – September 14, 2010) –  pihms, Inc. (www.pihms.com), a leading provider of integrated software solutions for tracking, measuring and managing human capital through pihms Leave Management, pihms Safety Solutions, and pihms Care Solutions, announced today that it has signed another new client contract and two relationship renewal and service expansions.

New Client
pihms’ new client contract is to provide Leave and Case Management support tools for the more than 15,000 U.S. based employees of the $10+ billion U.S. affiliate of a global company.

The Company reported that its newest client began its vendor selection with the goal of providing better internal customer service to its employees as they navigate through the process of requesting and securing approval for leaves. Patrick J. Kalnas, President and CEO of pihms, said, “Of great importance to this client, was the fact that our Leave and Case Management solution is not only customer friendly for both employee and management, but will help their organization reduce costs related to inappropriate and excessive leaves.”

Client Renewals and Expansions
The first current client, an integrated energy utility company, is renewing the pihms services provided to their onsite employee health clinic, and expanding the relationship by adding pihms’ integrated comprehensive Leave and Case Management Solutions for their entire base of U.S. employees. 

The other client, the North American entity of a global automotive corporation, is continuing its five plus year utilization of pihmsSafety Solutions™ for its multiple U.S. manufacturing facilities. The enhanced relationship will also now include the client’s 30+ Non-Manufacturing facilities across the U.S.

“The objective of each of these long time clients is to continue to leverage pihms’ proven track record and expertise, and allow its management to have more time to focus their energy on customers and business growth. The pihms relationship with these clients is a great example of how the pihms suite of solutions can be configured and expanded to meet the growing needs of the client,” Kalnas said.

About pihms:
pihms, Inc. is a Software as a Service (SaaS) provider focusing on best practices for tracking, measuring and managing human capital. pihms’ unique (and patented) process takes employee health, safety, leave management, and case management information from disparate sources and delivers it to the right decision makers at the right time. The workflow ensures that best practices are used to remain compliant with all FML and OSHA regulations. pihms, Inc. is headquartered in Pittsburgh with offices in Atlanta and Glasgow, Scotland. For more information visit the pihms website at www.pihms.com.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – September 14, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has named Christopher Vissman National Sales Manager, a new position. Mr. Vissman will be working from Nashville, TN, and Boca Raton, FL. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We are extremely fortunate and gratified to have Chris join Vicor as our National Sales Manager. Chris has more than 20 years of sales management experience, with the last 10 of these — most importantly to Vicor — focused on our market niche. We are confident that having Chris leading our national sales effort will ensure successful roll-out and reception of our PD2i Analyzer™,” stated Mr. Fater.

Concurrent with Mr. Vissman’s hire, Vicor has contracted with 10 independent sales representatives to cover multiple territories, including New England, Annapolis/DC, Atlanta, Dallas, Manhattan, Boston, Las Vegas, Denver, Knoxville, and Tucson.

Mr. Vissman is an accomplished sales executive with more than 20 years of building sales teams, creating winning sales strategies, and managing multiple sales channels. Most recently, he was a Principal of Medical Technologies, LLC, responsible for the hiring, training, and management of a national sales team introducing new technologies to primary care physicians, cardiologists, and endocrinologists. Prior to that, he was President of Innovative Diagnostics, Inc., start-up creator of a cardiac autonomic neuropathy diagnostic, for which Mr. Vissman developed a 40-person independent sales team, marketing materials, sales processes and programs, and successfully negotiated a national GPO contract. Earlier, Mr. Vissman was the National Sales Training Manager for CardioDynamics. During his tenure, he re-designed the Company’s new hire sales training program, which led to a 71% improvement in first month sales and 29% improvement in first quarter sales, and developed an advanced sales training program for representatives with between one and two years of experience, incorporating principles and practices of representatives consistently ranked in the top 20%. Before that, Mr. Vissman was District Manager for Polymedco, Inc., where he ranked among the top five sales representatives (among 40-45) in monthly new business closes in all categories. Earlier, Mr. Vissman held senior positions with non-medical industry companies, including Vice President of Sales & Marketing at Global Aqua Solutions; Territory Manager for Sika Corp., and District Sales Manager for Lochinvar Corp. Mr. Vissman holds a BA in Industrial Marketing and General Business from Western Michigan University.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™ (Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-15

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 13, 2010) – GrowthPoint Capital Corp. (“GrowthPoint”) is updating its reporting of security holdings in Vigil Health Solutions Inc. (“Vigil”), as a result of the one for twenty consolidation of the common shares of Vigil effective at the opening of trading on September 10, 2010.

As announced by GrowthPoint on August 17, 2010, pursuant to a private agreement, it acquired ownership on July 27, 2010 of $100,000 in debt of Vigil. Post-consolidation this $100,000 is now convertible into, 500,000 common shares of Vigil at a conversion price of $0.20 per common share, representing approximately 10.0% of Vigil’s post-consolidation common shares.

In addition to this $100,000 in convertible debt following Vigil’s share consolidation (and the expiry of 288,000 options prior to the consolidation) GrowthPoint and its affiliates also hold 496,450 common shares representing approximately 9.9% of Vigil’s post-consolidation common shares; 32,500 Deferred Stock Units representing approximately 0.7% of Vigil’s post-consolidation common shares; and 22,800 Stock Options representing approximately 0.5% of Vigil’s post-consolidation common shares. In aggregate, assuming the full exercise and conversion of the aforementioned securities, GrowthPoint and its affiliates would hold approximately 21.0% of the issued and post-consolidation common shares of Vigil.

In addition to owning or exercising control over the Vigil securities through GrowthPoint Capital Corp., GrowthPoint acts jointly or in concert with Greg Peet and GrowthPoint Ventures (VCC) Corp.

GrowthPoint acquired these securities for investment purposes. GrowthPoint may, depending on market conditions and other factors as well as applicable securities laws, acquire additional securities of Vigil through the facilities of the TSX Venture Exchange, private agreements or otherwise. GrowthPoint may, depending on market conditions, sell any or all of its common shares of Vigil.

For additional information, or for a copy of the early warning report filed in respect of the above transaction, please please see contact information below.